Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camillo Porta

Showing results (21-30 of 426) with videos related to

Pageof 43
Sort By:
Expert Opinion on Pharmacotherapy|January 24, 2012
3rd Pavia international symposium on advanced kidney cancerCamillo Porta, Sergio Bracarda
The Journal of Urology|October 20, 2009
Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitorsCamillo Porta, Robert A Figlin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2015
Urea-Based Cream to Prevent Sorafenib-Induced Hand-and-Foot Skin Reaction: Which Evidence?Francesca V Negri, Camillo Porta
International Journal of Urology : Official Journal of the Japanese Urological Association|April 12, 2017
Editorial Comment from Dr Porta et al. to Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USACamillo Porta, Laura Cosmai, Pietro Previtali
Frontiers in Oncology|May 1, 2014
Targeting PI3K/Akt/mTOR Signaling in CancerCamillo Porta, Chiara Paglino, Alessandra Mosca
Translational Andrology and Urology|January 28, 2016
Modifying sunitinib schedule in advanced kidney cancer patients: Reflections from the results of the renal EFFECT trialCamillo Porta, Carlo Ganini, Chiara Paglino
Immunotherapy|April 6, 2011
Is immunotherapy re-entering the kidney cancer arena from the back door? Considerations from the Phase I/II study of siltuximabCamillo Porta, Paolo Pedrazzoli, Chiara Paglino
Seminars in Thrombosis and Hemostasis|January 3, 2006
Autoimmunity in thrombotic thrombocytopenic purpuraCamillo Porta, Roberto Caporali, Carlomaurizio Montecucco
Urologia|November 15, 2011
Surgery and target agents for renal cell carcinoma treatment: the path between proper interactionCarlo Ganini, Bruno Rovereto, Camillo Porta
Hepatology (Baltimore, Md.)|January 26, 2019
Medical Treatment of Advanced Hepatocellular Carcinoma Patients: The Issue Is Not the Right Drug, but the Right PatientCamillo Porta, Chiara Broglia, Francesca Negri
Pageof 43

Showing results (21-30 of 426) with videos related to

Sort By:
Pageof 43
Expert Opinion on Pharmacotherapy|January 24, 2012
3rd Pavia international symposium on advanced kidney cancerCamillo Porta, Sergio Bracarda
The Journal of Urology|October 20, 2009
Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitorsCamillo Porta, Robert A Figlin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2015
Urea-Based Cream to Prevent Sorafenib-Induced Hand-and-Foot Skin Reaction: Which Evidence?Francesca V Negri, Camillo Porta
International Journal of Urology : Official Journal of the Japanese Urological Association|April 12, 2017
Editorial Comment from Dr Porta et al. to Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USACamillo Porta, Laura Cosmai, Pietro Previtali
Frontiers in Oncology|May 1, 2014
Targeting PI3K/Akt/mTOR Signaling in CancerCamillo Porta, Chiara Paglino, Alessandra Mosca
Translational Andrology and Urology|January 28, 2016
Modifying sunitinib schedule in advanced kidney cancer patients: Reflections from the results of the renal EFFECT trialCamillo Porta, Carlo Ganini, Chiara Paglino
Immunotherapy|April 6, 2011
Is immunotherapy re-entering the kidney cancer arena from the back door? Considerations from the Phase I/II study of siltuximabCamillo Porta, Paolo Pedrazzoli, Chiara Paglino
Seminars in Thrombosis and Hemostasis|January 3, 2006
Autoimmunity in thrombotic thrombocytopenic purpuraCamillo Porta, Roberto Caporali, Carlomaurizio Montecucco
Urologia|November 15, 2011
Surgery and target agents for renal cell carcinoma treatment: the path between proper interactionCarlo Ganini, Bruno Rovereto, Camillo Porta
Hepatology (Baltimore, Md.)|January 26, 2019
Medical Treatment of Advanced Hepatocellular Carcinoma Patients: The Issue Is Not the Right Drug, but the Right PatientCamillo Porta, Chiara Broglia, Francesca Negri
Pageof 43